{"id":"https://openalex.org/W2562349999","doi":"https://doi.org/10.1182/blood.v126.23.2980.2980","title":"UCHL1 Is a Biomarker of Aggressive Multiple Myeloma Required for Disease Progression","display_name":"UCHL1 Is a Biomarker of Aggressive Multiple Myeloma Required for Disease Progression","publication_year":2015,"publication_date":"2015-12-03","ids":{"openalex":"https://openalex.org/W2562349999","doi":"https://doi.org/10.1182/blood.v126.23.2980.2980","mag":"2562349999"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v126.23.2980.2980","doi":"https://doi.org/10.1182/blood.v126.23.2980.2980","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v126.23.2980.2980","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Sajjad Hussain","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sajjad Hussain","raw_affiliation_strings":["Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053223762","display_name":"Tibor Bedekovics","orcid":"https://orcid.org/0009-0003-9027-2324","observed_orcids":["https://orcid.org/0009-0003-9027-2324"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Tibor Bedekovics","raw_affiliation_strings":["Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007028620","display_name":"Marta Chesi","orcid":"https://orcid.org/0000-0002-4024-8225","observed_orcids":["https://orcid.org/0000-0002-4024-8225"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marta Chesi","raw_affiliation_strings":["Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004436275","display_name":"Peter Leif Bergsagel","orcid":"https://orcid.org/0000-0003-1523-7388","observed_orcids":["https://orcid.org/0000-0003-1523-7388"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leif Bergsagel","raw_affiliation_strings":["Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027265757","display_name":"Paul J. Galardy","orcid":"https://orcid.org/0000-0002-0322-8882","observed_orcids":["https://orcid.org/0000-0002-0322-8882"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul J. Galardy","raw_affiliation_strings":["Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5053223762"],"corresponding_institution_ids":["https://openalex.org/I1330342723"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.29810081,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"126","issue":"23","first_page":"2980","last_page":"2980"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/uchl1","display_name":"UCHL1","score":0.9639999866485596},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9380000233650208},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9679999947547913},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.9020000100135803},{"id":"https://openalex.org/keywords/ubiquitin-proteasome-system","display_name":"ubiquitin-proteasome system","score":0.906000018119812},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.7979999780654907},{"id":"https://openalex.org/keywords/1q21-amplification","display_name":"1q21 amplification","score":0.9980000257492065},{"id":"https://openalex.org/keywords/orthotopic-mouse-model","display_name":"orthotopic mouse model","score":0.7089999914169312},{"id":"https://openalex.org/keywords/b-cell-lymphoma","display_name":"B-cell lymphoma","score":0.5759999752044678},{"id":"https://openalex.org/keywords/plasmacytoma","display_name":"plasmacytoma","score":0.8769999742507935},{"id":"https://openalex.org/keywords/proteasome-inhibition","display_name":"proteasome inhibition","score":0.6740000247955322}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8815469741821289},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.8754155039787292},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.6645874977111816},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.6478860974311829},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.6394751071929932},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5677952766418457},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5320196151733398},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.49377354979515076},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48281678557395935},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.372180700302124},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.349327027797699},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.33922475576400757},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3068786859512329},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09560516476631165}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v126.23.2980.2980","doi":"https://doi.org/10.1182/blood.v126.23.2980.2980","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v126.23.2980.2980","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2220838850","https://openalex.org/W3047793622","https://openalex.org/W2560621325","https://openalex.org/W2561596542","https://openalex.org/W3140959911","https://openalex.org/W4249215835","https://openalex.org/W7211933906","https://openalex.org/W2429248020","https://openalex.org/W2313726441","https://openalex.org/W2341300320"],"abstract_inverted_index":{"Abstract":[0],"The":[1],"success":[2],"of":[3,43,73,81,99,124,130,161,202,212,221],"proteasome":[4],"inhibition":[5],"in":[6,18,27,36,57,136,143,158,166,231],"multiple":[7],"myeloma":[8,37,197,214],"highlights":[9],"the":[10,14,33,49,79,96,120,159],"critical":[11,156],"role":[12],"for":[13,119],"ubiquitin-proteasome":[15],"system":[16],"(UPS)":[17],"this":[19],"disease.":[20,204,233],"However,":[21],"there":[22],"has":[23],"been":[24],"little":[25],"progress":[26],"finding":[28,141],"more":[29],"specific":[30],"targets":[31],"within":[32],"UPS":[34],"involved":[35],"pathogenesis.":[38],"In":[39],"an":[40,188,218,228],"unbiased":[41],"screen":[42],"de-ubiquitinase":[44],"activity,":[45],"we":[46,67,106,192],"previously":[47],"found":[48,69,127,149,193],"ubiquitin":[50],"hydrolase":[51],"UCH-L1":[52,74,94,109,194,208],"to":[53,77,132,153],"be":[54,154,217,227],"frequently":[55],"over-expressed":[56],"B-cell":[58,83],"malignancies,":[59],"including":[60,145,181],"myeloma.":[61,125],"Using":[62,187],"a":[63,111,140,155,210],"transgenic":[64],"mouse":[65,190],"model,":[66,191],"also":[68,148],"that":[70,108,116,207,215],"aberrant":[71],"expression":[72],"is":[75,102,110,117,175,209],"sufficient":[76],"drive":[78],"development":[80],"spontaneous":[82],"lymphomas":[84],"and":[85,92,122,184,199,224],"plasmacytomas,":[86],"demonstrating":[87],"its":[88],"oncogenic":[89],"activity.":[90],"Whether":[91],"how":[93],"affects":[95],"clinical":[97],"behavior":[98],"myeloma,":[100],"however,":[101],"not":[103],"known.":[104],"Here":[105],"show":[107],"potent":[112],"negative":[113],"prognostic":[114],"factor":[115,157],"essential":[118],"dissemination":[121,198],"progression":[123,135],"We":[126,147,205],"high":[128,150],"levels":[129,152],"UCHL1":[131,151,170],"predict":[133],"early":[134],"newly":[137],"diagnosed":[138],"patients;":[139],"reversed":[142],"studies":[144],"bortezomib.":[146],"superiority":[160],"bortezomib":[162,222],"over":[163],"high-dose":[164],"dexamethasone":[165],"relapsed":[167],"patients.":[168],"High":[169],"partially":[171],"overlaps":[172],"with,":[173],"but":[174],"distinct":[176],"from,":[177],"known":[178],"genetic":[179],"risks":[180],"4p16":[182],"rearrangement":[183],"1q21":[185],"amplification.":[186],"orthotopic":[189],"depletion":[195],"delays":[196],"causes":[200],"regression":[201],"established":[203],"conclude":[206],"biomarker":[211],"aggressive":[213],"may":[216,225],"important":[219],"marker":[220],"response,":[223],"itself":[226],"effective":[229],"target":[230],"disseminated":[232],"Disclosures":[234],"Galardy:":[235],"Mission":[236],"Therapeutics:":[237],"Research":[238],"Funding.":[239]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2017-01-06T00:00:00"}